GCM
BTAI icon

Graham Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Graham Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,682
Closed -$897K – 1021
2022
Q1 		$897K Buy
2,682
+1,875
+232% +$543K 0.03% 351
2021
Q4 		$262K Buy
+807
New +$346K 0.01% 369

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Graham Capital Management's BTAI Position: Q2 2022 in Review

Graham Capital Management sold out of BioXcel Therapeutics (BTAI) in Q2 2022, closing a stake of 2,682 shares — an estimated $897K sold.

Graham Capital Management first reported a position in BTAI in Q4 2021 and held it in 2 quarters. The position peaked at $897K in Q1 2022. 94 funds tracked by Wall St. Rank hold BTAI as of Q2 2022.

  • Graham Capital Management reported no remaining BioXcel Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Graham Capital Management sold 2,682 BioXcel Therapeutics shares in Q2 2022, an estimated $897K.
  • Graham Capital Management first reported a position in BioXcel Therapeutics in Q4 2021 and held it in 2 quarters.
  • Graham Capital Management's BioXcel Therapeutics position peaked at $897K in Q1 2022.
  • 94 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2022.

Based on Graham Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.